Patient Care

According to the Ocular Hypertension Treatment Study, 5 risk factors are associated with high or low risk for primary open-angle glaucoma (POAG), with the intraocular pressure (IOP) historically being the “gold standard” and only modifiable risk factor.

Kristen Ingenito, MBA, gives key takeaways from her G360 presentation, "A bird’s eye view of innovation."

A look back on what's happened in optometry during the week of Jan. 28-Feb. 2.

A wave of infections across 11 states have been linked to artificial tear use, leading to permanent vision loss, hospitalization, and one death.

Kicking off AMD Awareness Month, give us your thoughts!

As our dependence on technology progresses, we have seen tremendous impact on all aspects of our lives—including our kids’ eyes and vision.

A look back on what's happened in optometry during the week of Jan. 21-Jan. 26.

A look back on what's happened in optometry during the week of Jan. 14-Jan. 19.

IntelliSep is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying emergency department patients with sepsis and contribute to rapid life-saving decisions.

Staying up-to-date on all things ocular is imperative in ocular surface disease.

A look back on what's happened in optometry during the week of Jan. 1-Jan. 5, 2023.

One individual’s habit can be the demise of good health.

Diagnosing and treating dry eye and meibomian gland dysfunction can be the foundation for practice growth—and patient satisfaction.

A meditation on the effects of putting off doctors' orders.

An increase in screen time has led to a rise in binocular vision disorders.

Look out for at-risk patients and prepare to establish treatment protocols.

Jim Sluck, VP of Marketing for Sight Sciences' TearCare, shares the impetus behind the company's fair access campaign.

Nidhi Rana, OD, discusses key highlights from her AAOpt 2022 presentation on pediatric red eye.

Derek Cunningham, OD, FAAO, gives key takeaways from his AAOpt 2022 discussion, "Back to the basics: The importance of treating inflammation AND obstruction for dry eye."

Jeff Nau, PhD, president and CEO of Oyster Point Pharma shares an update on the company's Tyrvaya product.

Three experts in myopia control convened at the Optometry Times EyeCon meeting to discuss methods to control this burgeoning global epidemic.

Considering safety and efficacy of new drops and the potential impact on your patients.

According to the authors, a patient with bilateral choroid metastases from breast cancer experienced "a dramatic response" after a combination treatment of abemaciclib and fulvestrant.

Jacqueline Theis, OD, FAAO, gives key takeaways from her discussion on treating photophobia in patients, which she presented during the 2022 American Academy of Optometry meeting.

As technology advances and choices grow, you need to personalize patients’ options.